Abstract
This study investigated the vasoactive effects of des-aspartate-angiotensin-I (DAA-I) in male Wistar rats on whole body vascular bed, isolated perfused kidneys, and aortic rings. Dose–response curves to DAA-I were compared with those to angiotensin II (Ang II). The Ang II-type-1 (AT1) receptor blocker, losartan, was used to evaluate the role of AT1 receptors in the responses to DAA-I. Studies were also conducted of the responsiveness in aortic rings after endothelium removal, nitric oxide synthase inhibition, or AT2 receptor blockade. DAA-I induced a dose-related systemic pressor response that was shifted to the right compared with Ang II. Losartan markedly attenuated the responsiveness to DAA-I. DAA-I showed a similar pattern in renal vasculature and aortic rings. In aortic rings, removal of endothelium and nitric oxide inhibition increased the sensitivity and maximal response to DAA-I and Ang II. AT2 receptor blockade did not significantly affect the responsiveness to DAA-I. According to these findings, DAA-I increases the systemic blood pressure and vascular tone in conductance and resistance vessels via AT1 receptor activation. This vasoconstrictor effect of DAA-I participates in the homeostatic control of arterial pressure, which can also contribute to the pathogenesis of hypertension. DAA-I may therefore be a potential therapeutic target in cardiovascular disease.
Funder
Carlos III Health Institute of Spain
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference46 articles.
1. International union of pharmacology. XXIII. The angiotensin II receptors;De Gasparo;Pharmacol. Rev.,2000
2. Physiology of Local Renin-Angiotensin Systems
3. Counterregulatory Actions of Angiotensin-(1-7)
4. Biochemistry and kinetics of the renin–angiotensin system;Skeggs;Fed. Proc.,1967
5. Mass-Spectrometric Identification of a Novel Angiotensin Peptide in Human Plasma